<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1759">
  <stage>Registered</stage>
  <submitdate>20/11/2007</submitdate>
  <approvaldate>20/11/2007</approvaldate>
  <nctid>NCT00561925</nctid>
  <trial_identification>
    <studytitle>VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients</studytitle>
    <scientifictitle>A Randomised, Double Blind, Double Dummy, Parallel Group, Active Controlled Trial to Evaluate the Antiviral Efficacy of 400 mg QD neVirapine Extended Release Formulation in Comparison to 200 mg BID neVirapinE Immediate Release in Combination With Truvada速 in Antiretroviral Therapy na誰ve HIV-1 Infected Patients (VERxVE)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2007-003654-29</secondaryid>
    <secondaryid>1100.1486</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV Infections</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - nevirapine IR
Treatment: drugs - nevirapine XR

Experimental: nevirapine XR - 400 mg QD

Active Comparator: nevirapine IR - 200 mg BID


Treatment: drugs: nevirapine IR
200 mg BID

Treatment: drugs: nevirapine XR
400 mg QD

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Comparison of Proportion of Virologic Response at Week 48 Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population - Primary endpoint was the number of patients with a sustained virologic response through week 48 using LLOQ = 50 copies/mL</outcome>
      <timepoint>week 48</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Kaplan-Meier Estimates of the Proportions of Patients Without Loss of Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population</outcome>
      <timepoint>week 0 to 144</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of Sustained Virologic Response at Week 144 Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population - Endpoint was the number of patients with a sustained virologic response through week 144 using LLOQ = 50 copies/mL</outcome>
      <timepoint>week 144</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Kaplan-Meier Estimates for Time to New AIDS or AIDS-related Progression Event or Death, Full Analysis Set Population</outcome>
      <timepoint>week 0 to 144</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Comparison of HIV-1 Viral Load (log10 Copies/mL) Change From Baseline at Week 144, Full Analysis Set Population</outcome>
      <timepoint>baseline, week 144</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Comparison of CD4+ Cell Count (Cells/Cubic Millimeter) Change From Baseline at Week 144, Full Analysis Set Population</outcome>
      <timepoint>baseline, week 144</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Occurrence of Rashes - Frequency of patients with drug related rash events by functional grouping</outcome>
      <timepoint>until last patient completed 144 weeks (up to 193 weeks)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Occurrence of Elevations in Laboratory Measurement by DAIDS Grade</outcome>
      <timepoint>until last patient completed 144 weeks (up to 193 weeks)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Kaplan -Meier Estimate of Cumulative Probability of Permanent Discontinuation of Study Medication</outcome>
      <timepoint>week 0 to 144</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Kaplan -Meier Estimate of Cumulative Probability of Grade 3 or 4 ALT/AST Abnormalities</outcome>
      <timepoint>week 0 to 72</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Kaplan -Meier Estimate of Cumulative Probability of Grade 3 or 4 Asymptotic Transaminases Abnormalities</outcome>
      <timepoint>week 0 to 72</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Kaplan -Meier Estimate of Cumulative Probability of Clinical Hepatic Events</outcome>
      <timepoint>week 0 to 72</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Kaplan -Meier Estimate of Cumulative Probability of Group III or IV Drug-related Rash</outcome>
      <timepoint>week 0 to 72</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Relative Bioavailability Trough C_pre,ss,1 - Relative bioavailability measured of trough concentrations. Analysis based on adjusted by-treatment geometric means, the adjusted geometric mean ratio of NVP XR : NVP IR and it's 90% confidence interval with p-value and the inter-individual geometric coefficient of variation.</outcome>
      <timepoint>week 132</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Occurrence of Hepatic Events - Frequency of patients with hepatitis symptoms</outcome>
      <timepoint>until last patient completed 144 weeks (up to 193 weeks)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          1. Signed informed consent in accordance with Good Clinical Practice and local regulatory
             requirements prior to trial participation

          2. HIV-1 infected males or females &gt;= 18 years of age with positive serology (ELISA)
             confirmed by Western blot

          3. No previous antiretroviral treatment

          4. Males with CD4+ counts &gt;50 - &lt;400 cells/ml or females with CD4+ counts &gt;50-&lt;250
             cells/ml

          5. Adequate renal function defined as a calculated creatinine clearance (CLCr) greater
             than or equal to 50 mL/min according to the Cockcroft-Gault formula as follows:

             Male: (140 - age in years) x (weight in kg) divided by 72 x (serum creatinine in
             mg/dl) = CLCr (mL/min).

             Female: (140 - age in years) x (weight in kg) divided by 72 x (serum creatinine in
             mg/dl) x 0.85 = CLCr (mL/min).

          6. Karnofsky score &gt;70 (see Appendix 10.4)

          7. An HIV-1 viral load of 1,000 copies/mL

          8. Willingness to initiate CD4+ cell count-guided chemoprophylaxis to prevent important
             opportunistic infections as defined in Appendix 10.2

          9. Willingness to abstain from ingesting substances which may alter plasma study drug
             levels by interaction with the cytochrome P450 system (listed in Appendix 10.3) during
             the study.

         10. For centers participating in the PK substudy only: Written informed consent in
             accordance with GCP and local legislation for participation in the PK substudy.
             Refusal to participate in the PK substudy is not an exclusion criterion for
             participation in the trial. Only study centers with previous experience and equipped
             in handling PK samples are eligible for participation in the substudy.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          1. Active drug abuse or chronic alcoholism at the investigator's discretion

          2. Active hepatitis B or C disease, defined as HBsAg-positive and HBV-DNA-positive or
             HCV-RNA-positive

          3. Female patients of child-bearing potential who: are pregnant at screening; are breast
             feeding; are planning to become pregnant; are not willing to use a barrier method of
             contraception, or; are not willing to use methods of contraception other than ethinyl
             estradiol containing oral contraceptives Note: During participation in this study,
             females and males have to use barrier methods of contraception in addition or instead
             of ethinyl estradiol containing oral contraceptives.

          4. Laboratory parameters &gt;DAIDS Grade 2

          5. ALT/AST &gt; DAIDS Grade 1

          6. Hypersensitivity to any ingredients of the test products

          7. Previous use of Viramune速 (nevirapine) or any other antiretroviral agents (does not
             include use of single dose NVP for the prevention of mother to child transmission)

          8. Resistance to NNRTIs or either one of the components of Truvada速 (emtricitabine or
             tenofovir disoproxil fumarate) or lamivudine (3TC) based on HIV-1 genotypic resistance
             testing report obtained at screening

          9. Patients who are receiving other concomitant treatments which are not permitted, as
             described in the prescribing information

         10. Use of investigational medications (any experimental agent other than the study
             regimen) within 30 days before study entry or during the trial

         11. Use of immunomodulatory drugs within 30 days before study entry or during the trial
             (e.g., interferon, cyclosporin, hydroxyurea, interleukin 2)

         12. Patients who have been diagnosed with malignant disease

         13. Patients who in the opinion of the investigator are not candidates for inclusion in
             the study

         14. Patient with Progressive Multifocal Leukoencephalopathy (PML), Visceral Kaposi's
             Sarcoma (KS), and/or any lymphoma

         15. Any AIDS defining illness that is unresolved, symptomatic or not stable on treatment
             for at least 12 weeks at screening visit</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>1068</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD</recruitmentstate>
    <hospital>1100.1486.6101 Boehringer Ingelheim Investigational Site - Darlinghurst</hospital>
    <hospital>1100.1486.6102 Boehringer Ingelheim Investigational Site - Darlinghurst</hospital>
    <hospital>1100.1486.6104 Boehringer Ingelheim Investigational Site - Surry Hills</hospital>
    <hospital>1100.1486.6103 Boehringer Ingelheim Investigational Site - Brisbane</hospital>
    <postcode> - Darlinghurst</postcode>
    <postcode> - Surry Hills</postcode>
    <postcode> - Brisbane</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Idaho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Capital Federal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Mar del Plata</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Quilmes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Rosario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brugge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Charleroi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Li竪ge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Botswana</country>
      <state>Francistown</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Botswana</country>
      <state>Gaborone</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Angers</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bondy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Brest Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Caen cedex 5</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clamart</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon Cedex 3</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice cedex 3</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Etienne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulon cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villeneuve St Georges cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bochum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dortmund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>D端sseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Erlangen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt/Main</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kiel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>K旦ln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>M端nchen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>M端nster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Osnabr端ck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm/Donau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>W端rzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin 8</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Palermo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pescara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Treviso</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Verbania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Guadalajara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Le坦n</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Arnhem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Zwolle</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bydgoszcz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Chorzow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Amadora</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisboa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Ponce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Bloemfontein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Cape Town</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Edenvale</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Johannesburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Nelspruit</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Port Elizabeth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Pretoria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alcal叩 de Henares (Madrid)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>L'Hospitalet de Llobregat</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Mataro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Basel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Gen竪ve</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>La Chaux-de-Fonds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Lausanne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Lugano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>St. Gallen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Z端rich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Plaistow, London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boehringer Ingelheim</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of this study is to evaluate the efficacy of 400 mg QD nevirapine
      extended release (NVP XR) formulation versus 200 mg BID nevirapine immediate release (NVP IR)
      in ARV therapy na誰ve HIV-1 infected patients after 48 weeks of treatment. Secondary
      objectives are to evaluate safety and pharmacokinetics of NVP XR and NVP IR.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00561925</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Boehringer Ingelheim</name>
      <address>Boehringer Ingelheim</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>